Adam Ang
It will use the funds to deepen its presence across Asia.
The company has also launched a distribution unit in the United States.
The company plans to bring its technology to 10,000 more doctors in the country.
The company is also close to getting its patent for the Us2.v1 software recognised in the US.
The secondary care platform will soon offer online doctor consultations as part of its expansion into primary care.
They will provide the first access to an AI-enabled minimal residual disease test in India.
Two variants of the Annalise CXR Edge products will be offered in Australia.
The AI solution has been trained based on a data set of 3.2 billion patient visits.
Also, Standigm has partnered with Merck Korea for AI drug discovery research.
The investment will be used for its Asia-Pacific expansion while leveraging Metro's presence.